CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade CNS Pharmaceuticals, Inc. - CNSP CFD

0.3628
6.66%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.0322
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.01
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 0.35
Open* 0.3651
1-Year Change* -65.45%
Day's Range* 0.345 - 0.3733
52 wk Range 0.16-1.38
Average Volume (10 days) 92.00K
Average Volume (3 months) 3.97M
Market Cap 8.41M
P/E Ratio -100.00K
Shares Outstanding 40.03M
Revenue N/A
EPS -0.35
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Mar 1, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 28, 2024 0.3733 0.0083 2.27% 0.3650 0.3733 0.3450
Mar 27, 2024 0.3500 -0.0050 -1.41% 0.3550 0.3686 0.3350
Mar 26, 2024 0.3597 0.0104 2.98% 0.3493 0.3626 0.3391
Mar 25, 2024 0.3450 -0.0100 -2.82% 0.3550 0.3625 0.3450
Mar 22, 2024 0.3478 0.0028 0.81% 0.3450 0.3719 0.3388
Mar 21, 2024 0.3450 -0.0111 -3.12% 0.3561 0.3691 0.3450
Mar 20, 2024 0.3568 0.0118 3.42% 0.3450 0.3750 0.3410
Mar 19, 2024 0.3362 -0.0248 -6.87% 0.3610 0.3695 0.3288
Mar 18, 2024 0.3644 -0.0048 -1.30% 0.3692 0.3692 0.3550
Mar 15, 2024 0.3807 0.0357 10.35% 0.3450 0.3807 0.3450
Mar 14, 2024 0.3786 0.0036 0.96% 0.3750 0.3850 0.3161
Mar 13, 2024 0.3807 -0.0446 -10.49% 0.4253 0.4253 0.3761
Mar 12, 2024 0.4150 -0.0219 -5.01% 0.4369 0.4380 0.4099
Mar 11, 2024 0.4260 -0.0152 -3.45% 0.4412 0.4651 0.4250
Mar 8, 2024 0.4176 0.0026 0.63% 0.4150 0.4420 0.3903
Mar 7, 2024 0.4339 -0.0211 -4.64% 0.4550 0.4550 0.3858
Mar 6, 2024 0.4350 0.0400 10.13% 0.3950 0.4450 0.3750
Mar 5, 2024 0.3672 -0.0044 -1.18% 0.3716 0.4025 0.3450
Mar 4, 2024 0.3360 -0.0056 -1.64% 0.3416 0.3710 0.3150
Mar 1, 2024 0.3162 0.0412 14.98% 0.2750 0.3316 0.2650

CNS Pharmaceuticals, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total revenue 0 0 0 0 0
Total Operating Expense 14.0273 9.45461 3.83298 7.16863 0.21511
Selling/General/Admin. Expenses, Total 4.68084 4.39287 1.97864 0.86052 0.18247
Research & Development 9.34645 5.06173 1.85433 0.02127 0.03264
Unusual Expense (Income) 0 6.28684 0
Operating Income -14.0273 -9.45461 -3.83298 -7.16863 -0.21511
Interest Income (Expense), Net Non-Operating -0.00929 -0.00326 -0.04423 -0.0467 -0.00426
Other, Net 0 -0.17657 0
Net Income Before Taxes -14.0366 -9.45787 -3.87721 -7.3919 -0.21936
Net Income After Taxes -14.0366 -9.45787 -3.87721 -7.3919 -0.21936
Net Income Before Extra. Items -14.0366 -9.45787 -3.87721 -7.3919 -0.21936
Total Extraordinary Items 0
Net Income -14.0366 -9.45787 -3.87721 -7.3919 -0.21936
Income Available to Common Excl. Extra. Items -14.0366 -9.45787 -3.87721 -7.3919 -0.21936
Income Available to Common Incl. Extra. Items -14.0366 -9.45787 -3.87721 -7.3919 -0.21936
Diluted Net Income -14.0366 -9.45787 -3.87721 -7.3919 -0.21936
Diluted Weighted Average Shares 26.3533 16.6184 13.6479 15.712 15.712
Diluted EPS Excluding Extraordinary Items -0.53263 -0.56912 -0.28409 -0.47046 -0.01396
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -0.53263 -0.56912 -0.28409 -0.07033 -0.01396
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total revenue 0 0 0 0 0
Total Operating Expense 2.78177 2.79292 3.8134 3.81132 3.60966
Selling/General/Admin. Expenses, Total 1.26041 0.89633 1.23539 1.14634 1.40278
Research & Development 1.52136 1.89658 2.57802 2.66498 2.20687
Operating Income -2.78177 -2.79292 -3.8134 -3.81132 -3.60966
Interest Income (Expense), Net Non-Operating -0.00257 -0.00224 -0.00095 -0.00235 -0.00375
Net Income Before Taxes -2.78434 -2.79515 -3.81435 -3.81367 -3.6134
Net Income After Taxes -2.78434 -2.79515 -3.81435 -3.81367 -3.6134
Net Income Before Extra. Items -2.78434 -2.79515 -3.81435 -3.81367 -3.6134
Net Income -2.78434 -2.79515 -3.81435 -3.81367 -3.6134
Income Available to Common Excl. Extra. Items -2.78434 -2.79515 -3.81435 -3.81367 -3.6134
Income Available to Common Incl. Extra. Items -2.78434 -2.79515 -3.81435 -3.81367 -3.6134
Diluted Net Income -2.78434 -2.79515 -3.81435 -3.81367 -3.6134
Diluted Weighted Average Shares 38.8083 27.8385 27.4438 25.4327 24.6644
Diluted EPS Excluding Extraordinary Items -0.07175 -0.10041 -0.13899 -0.14995 -0.1465
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.07175 -0.10041 -0.13899 -0.14995 -0.1465
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total Current Assets 7.47745 15.4958 7.89391 0.58813 0.16219
Cash and Short Term Investments 5.00452 14.0395 7.24129 0.28274 0.11054
Cash & Equivalents 5.00452 14.0395 7.24129 0.28274 0.11054
Prepaid Expenses 2.47293 1.45635 0.65262 0.033 0.05165
Other Current Assets, Total 0 0.2724 0
Total Assets 8.75739 15.8534 7.91208 0.68333 0.16219
Other Long Term Assets, Total 1.26383 0.33414 0 0.0952 0
Total Current Liabilities 2.13557 1.90543 0.311 1.23263 0.22073
Accounts Payable 1.52282 0.94633 0.24367 0.12807 0.0425
Payable/Accrued 0 0.04583 0.00079 0.015
Accrued Expenses 0.22495 0.5198 0.0215 0.0236 0.0414
Notes Payable/Short Term Debt 0.38779 0.43929 0 0.31692 0.12183
Other Current Liabilities, Total 0 0.76325 0
Total Liabilities 2.13557 1.90543 0.311 1.23263 0.22073
Total Long Term Debt 0 0 0 0 0
Total Equity 6.62182 13.948 7.60108 -0.5493 -0.05853
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.02793 0.02386 0.01645 0.0127 0.01027
Additional Paid-In Capital 41.5768 34.8705 19.0731 7.04927 0.15056
Retained Earnings (Accumulated Deficit) -34.9829 -20.9463 -11.4885 -7.61126 -0.21936
Total Liabilities & Shareholders’ Equity 8.75739 15.8534 7.91208 0.68333 0.16219
Total Common Shares Outstanding 27.9272 23.8561 16.4502 15.712 15.712
Property/Plant/Equipment, Total - Net 0.01611 0.02343 0.01817
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total Current Assets 14.7332 7.47745 11.1558 13.8835 12.7864
Cash and Short Term Investments 12.4405 5.00452 8.32622 6.88557 11.0752
Cash & Equivalents 12.4405 5.00452 8.32622 6.88557 11.0752
Total Receivables, Net 3.70177 0.13265
Accounts Receivable - Trade, Net 0.13265 0.13265
Prepaid Expenses 2.29267 2.47293 2.82961 3.29615 1.57852
Total Assets 15.8719 8.75739 11.5075 14.2385 13.1446
Property/Plant/Equipment, Total - Net 0.01273 0.01611 0.01753 0.0209 0.02411
Other Long Term Assets, Total 1.12596 1.26383 0.33414 0.33414 0.33414
Total Current Liabilities 1.0693 2.13557 2.40743 1.83075 1.90176
Accounts Payable 0.48972 1.52282 1.46157 0.89249 1.05768
Accrued Expenses 0.30701 0.22495 0.90122 0.76068 0.53494
Notes Payable/Short Term Debt 0.27257 0.38779 0.04463 0.17758 0.30913
Total Liabilities 1.0693 2.13557 2.40743 1.83075 1.90176
Total Long Term Debt 0 0 0 0 0
Total Equity 14.8026 6.62182 9.10007 12.4078 11.2429
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 0.04003 0.02793 0.02746 0.02738 0.02535
Additional Paid-In Capital 52.5298 41.5768 41.2604 40.7538 35.7772
Retained Earnings (Accumulated Deficit) -37.7673 -34.9829 -32.1878 -28.3734 -24.5597
Total Liabilities & Shareholders’ Equity 15.8719 8.75739 11.5075 14.2385 13.1446
Total Common Shares Outstanding 40.0325 27.9272 27.4607 27.3795 25.3528
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Net income/Starting Line -14.0366 -9.45787 -3.87721 -7.3919 -0.21936
Cash From Operating Activities -13.5383 -7.31802 -3.55347 -0.71639 -0.1122
Non-Cash Items 1.72384 1.29498 0.7474 6.59174 0.05992
Cash Taxes Paid 0 0 0 0 0
Cash Interest Paid 0.00977 0.00171 0.00399 0 0
Changes in Working Capital -1.23864 0.83378 -0.42562 0.08378 0.04725
Cash From Financing Activities 4.50908 14.1342 10.2598 1.16098 0.22274
Financing Cash Flow Items 0 -0.045 0 0.47048 0
Issuance (Retirement) of Stock, Net 4.98657 14.2222 10.2948 0.3905 0.10092
Issuance (Retirement) of Debt, Net -0.47749 -0.04308 -0.035 0.3 0.12183
Net Change in Cash -9.03498 6.79821 6.68616 0.44459 0.11054
Cash From Operating Activities 0.01307 0.0111 0.00196
Cash From Investing Activities -0.00575 -0.01795 -0.02012
Capital Expenditures -0.00575 -0.01795 -0.02012
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line -2.78434 -14.0366 -11.2414 -7.42708 -3.6134
Cash From Operating Activities -3.0772 -13.5383 -10.3015 -8.30599 -3.30805
Cash From Operating Activities 0.00338 0.01307 0.00958 0.00621 0.003
Non-Cash Items 0.33669 1.72384 1.40694 0.90029 0.43068
Cash Taxes Paid 0 0 0 0 0
Cash Interest Paid 0.00288 0.00977 0.00721 0.00721 0.00421
Changes in Working Capital -0.63292 -1.23864 -0.4766 -1.78541 -0.12833
Cash From Investing Activities 0 -0.00575 -0.00367 -0.00367 -0.00367
Capital Expenditures 0 -0.00575 -0.00367 -0.00367 -0.00367
Cash From Financing Activities 10.5132 4.50908 4.59191 1.15574 0.34743
Issuance (Retirement) of Stock, Net 10.6284 4.98657 4.98657 1.41745 0.47759
Issuance (Retirement) of Debt, Net -0.11522 -0.47749 -0.39466 -0.26171 -0.13016
Net Change in Cash 7.43598 -9.03498 -5.71327 -7.15392 -2.96429
Financing Cash Flow Items 0 0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

CNS Pharmaceuticals, Inc. Company profile

About CNS Pharmaceuticals Inc

CNS Pharmaceuticals Inc. is a clinical pharmaceutical company. The Company is focused on development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The Company is developing its lead drug candidate, Berubicin for the treatment of glioblastoma. Glioblastoma are tumors that arise from astrocytes, which are star-shaped cells making up the supportive tissue of the brain. Berubicin is an anthracycline, a class of drugs that are among the chemotherapy drugs, which intercalates into Deoxyribonucleic acid (DNA) and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein synthesis. The Company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, CNS Pharmaceuticals Inc revenues was not reported. Net loss increased 48% to $14M. Higher net loss reflects Research and development increase of 85% to $9.3M (expense), Selling/General/Admin Expense increase of 7% to $4.7M (expense), Interest expense increase from $3K to $9K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.57 to -$0.53.

Industry: Biotechnology & Medical Research (NEC)

2100 West Loop S Ste 900
HOUSTON
TEXAS 77027-3522
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

Gold

2,233.43 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.80

XRP/USD

0.62 Price
-2.650% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

ETH/USD

3,540.34 Price
-0.930% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

BTC/USD

69,992.70 Price
-1.220% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading